EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT01435031

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01435031
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01435031. Allocation not applicable; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2014-11-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Acronym
EXPERT CTO
Condition
Chronic Total Occlusion (CTO)
Intervention (Device)
CTO Treatment Device
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct01435031
Content hash
9709f8a08e9daf02146ac4035f43b19fbc1c1d0f024f1c40e85349e3819c9185